Showing results (191-200 of 322) with videos related to

Sort By:
Pageof 33
BJU International|April 22, 2008
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancerRuth E Langley, Ian F Godsland, Howard Kynaston, et al.
International Journal of Radiation Oncology, Biology, Physics|July 29, 2026
Defining Intraprostatic Gross Tumor Volume and Micro-boosting through Consensus: A Contour-Based Modified Delphi ConsensusLucas C Mendez, Costas Zamboglou, Shafak Al-Uwini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 25, 2025
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trialSzeyi Ng, Lucy S Kilburn, Anna M Kirby, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 8, 2026
Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility studySian Cooper, Sophie Alexander, Charlotte Cherry, et al.
The Lancet. Oncology|March 18, 2008
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort studyRoy Vergis, Catherine M Corbishley, Andrew R Norman, et al.
Frontiers in Oncology|April 20, 2017
R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation OncologyHelena M Verkooijen, Linda G W Kerkmeijer, Clifton D Fuller, et al.
European Urology|October 23, 2025
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B StudyRagu Ratnakumaran, Douglas H Brand, Archana Sasitharan, et al.
Cancer Immunology, Immunotherapy : CII|June 26, 2012
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling timeLindsey Chudley, Katy McCann, Ann Mander, et al.
European Urology|December 9, 2020
Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 TrialSyed A Hussain, Nuria Porta, Emma Hall, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 14, 2012
Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trialSarah L Gulliford, Aisha B Miah, Sinead Brennan, et al.
Pageof 33